Opko Health (OPK) AI Stock Analysis

• Market Cap: $1.07B
• Dividend Yield: N/A
• Average Volume (3M): 2.18M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.83
• Revenue Growth: -9.75%
• EPS Growth: -31.28%
• Country: US
• Employees: 2,997
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 0.03
• Shares Outstanding: 767,701,300
• 10 Day Avg. Volume: 1,466,492
• 30 Day Avg. Volume: 2,176,778
• PEG Ratio: 0.28
• Price to Book (P/B): 0.75
• Price to Sales (P/S): 1.43
• P/FCF Ratio: -4.89
• Enterprise Value/Market Cap: 0.00
• Enterprise Value/Revenue: 0.00
• Enterprise Value/Gross Profit: 0.00
• Enterprise Value/Ebitda: 0.00
• 1Y Price Target: $2.75
• Price Target Upside: 79.74% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 51 Neutral
• Price Target: $1.50 ▼(-1.96% Downside)

Opko Health's overall stock score is primarily impacted by its financial difficulties, including declining revenues and negative profitability. While strategic initiatives and partnerships highlighted in the earnings call provide some optimism, the technical and valuation metrics remain weak, reflecting ongoing challenges.

Positive Factors

Strategic Partnerships

The collaboration with Regeneron to develop multispecific antibodies enhances Opko's R&D capabilities and could lead to innovative treatments, strengthening its competitive position in the biopharmaceutical industry.

Pipeline Advancements

Advancements in the pharmaceutical pipeline, including clinical trials, indicate potential future revenue streams and demonstrate Opko's commitment to innovation and long-term growth.

FDA Approval

FDA approval for the 4Kscore test without digital rectal examination expands its marketability, potentially increasing diagnostic segment revenues and strengthening Opko's market position.

Negative Factors

Revenue Decline

A decline in revenue indicates challenges in maintaining market share and operational efficiency, which could affect long-term financial stability and growth prospects.

Negative Profitability

Sustained negative profitability, exacerbated by significant expenses, highlights financial instability and could limit Opko's ability to invest in growth opportunities.

Cash Flow Issues

Negative operating cash flow suggests inefficiencies in converting revenue into cash, which may constrain Opko's operational flexibility and ability to fund future initiatives.

Opko Health Business Overview & Revenue Model

Company Description

Opko Health, Inc. is a diversified healthcare company focused on developing and commercializing innovative health solutions. The company operates primarily in the pharmaceuticals and diagnostics sectors, offering a range of products including proprietary pharmaceuticals, diagnostic products, and novel drug delivery systems. Opko Health is known for its commitment to advancing medical technology and improving patient outcomes through its core products such as the 4Kscore Test, a diagnostic test for prostate cancer, and a portfolio of pharmaceutical products that address various medical needs.

How the Company Makes Money

Opko Health generates revenue through multiple streams, primarily from the sale of pharmaceuticals and diagnostic tests. The company markets its proprietary drugs and therapies, including treatments for endocrinology and urology. Additionally, Opko's 4Kscore Test contributes significantly to its revenue, being a leading diagnostic tool for prostate cancer detection. The company also engages in partnerships and collaborations with other healthcare organizations, which can result in shared revenue from co-developed products or licensing agreements. Furthermore, Opko has a focus on research and development, which may lead to new product offerings and additional revenue streams in the future.

Opko Health Financial Statement Overview

Summary

Opko Health is facing substantial financial difficulties, with declining revenues, negative profitability, and cash flow challenges. While the balance sheet shows some stability in terms of leverage, the negative returns and cash flow inefficiencies pose significant risks.

Income Statement

Opko Health's income statement reveals a challenging financial environment. The company has experienced declining revenue over the past few years, with a TTM revenue growth rate of -3.31%. Profitability metrics are concerning, with a negative net profit margin of -26.68% and an EBIT margin of -5.29% in the TTM period. The gross profit margin has decreased to 32.65% from 43.61% in the previous year. These figures indicate significant pressure on the company's profitability and operational efficiency.

Balance Sheet

The balance sheet of Opko Health shows moderate leverage with a debt-to-equity ratio of 0.31 in the TTM period, which is an improvement from previous years. However, the return on equity remains negative at -13.18%, indicating that the company is not generating positive returns for its shareholders. The equity ratio stands at a reasonable level, suggesting a stable capital structure despite the ongoing losses.

Cash Flow

Opko Health's cash flow statement highlights significant challenges. The company has negative operating cash flow and free cash flow in the TTM period, with a free cash flow growth rate of -18.22%. The operating cash flow to net income ratio is -1.40, reflecting inefficiencies in converting income into cash. Although the free cash flow to net income ratio is positive at 1.08, it is primarily due to the negative net income, indicating cash flow issues.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	642.07M	713.14M	863.50M	1.00B	1.77B	1.44B
Gross Profit	247.95M	311.03M	318.13M	288.22M	581.52M	541.00M
EBITDA	45.12M	135.28M	-65.52M	-270.81M	83.57M	155.98M
Net Income	-140.80M	-53.22M	-188.86M	-328.40M	-30.14M	30.59M
Balance Sheet
Total Assets	2.00B	2.20B	2.01B	2.17B	2.40B	2.47B
Cash, Cash Equivalents and Short-Term Investments	415.20M	431.94M	95.88M	153.19M	134.71M	72.21M
Total Debt	395.42M	504.44M	326.56M	305.55M	254.75M	294.57M
Total Liabilities	690.02M	834.76M	622.48M	605.61M	714.59M	801.51M
Stockholders Equity	1.31B	1.37B	1.39B	1.56B	1.69B	1.67B
Cash Flow
Free Cash Flow	-212.06M	-208.50M	-44.47M	-119.77M	6.18M	5.79M
Operating Cash Flow	-197.03M	-183.49M	-28.20M	-95.19M	38.34M	39.48M
Investing Cash Flow	348.33M	352.21M	-18.20M	91.04M	35.95M	-18.33M
Financing Cash Flow	-140.19M	184.17M	-11.30M	22.97M	-10.35M	-35.08M

Opko Health Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.53
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OPK, the sentiment is Negative. The current price of 1.53 is above the 20-day moving average (MA) of 1.32, above the 50-day MA of 1.42, and above the 200-day MA of 1.44, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 47.50 is Neutral, neither overbought nor oversold. The STOCH value of 79.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for OPK.

Opko Health Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CDNA	77 Outperform	$883.61M	14.41	24.11%	―	14.46%	―
CSTL	63 Neutral	$1.13B	―	-2.69%	―	10.15%	-295.52%
FLGT	57 Neutral	$859.06M	―	-3.80%	―	13.60%	74.64%
NEO	55 Neutral	$1.54B	―	-12.99%	―	10.10%	-44.29%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
OPK	51 Neutral	$1.07B	-5.64	-13.32%	―	-9.75%	-31.28%
MYGN	49 Neutral	$660.89M	-1.64	-72.52%	―	0.21%	-233.51%

Opko Health Corporate Events

Opko Health Sells BioReference Assets to Labcorp

On September 15, 2025, OPKO Health, Inc. completed the sale of certain assets of its subsidiary, BioReference Health, to Laboratory Corporation of America Holdings (Labcorp) for up to $225 million. This transaction, which includes BioReference’s oncology and clinical testing services, marks a strategic shift for OPKO, allowing it to focus on core clinical testing operations and the growth of its 4Kscore Test franchise, while Labcorp expands its oncology services portfolio.